NCT02552953 is a Phase 1 clinical trial of CYC065 in Cancer, sponsored by Cyclacel Pharmaceuticals, Inc..

Who is sponsoring NCT02552953?

NCT02552953 is sponsored by Cyclacel Pharmaceuticals, Inc..

What drugs are being tested in NCT02552953?

Interventions in NCT02552953: CYC065.

Is NCT02552953 still recruiting?

NCT02552953 is currently completed. Last updated 31 May 2024.

Last reviewed 2024-05-31 · How we verify

NCT02552953

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

Completed Phase 1 Last updated 31 May 2024

What this trial tests

Phase 1 trial testing CYC065 in Cancer in 60 participants. Completed in 25 August 2023.

Timeline

28 September 2015

Primary endpoint
4 October 2022

25 August 2023

Quick facts

Lead sponsor	Cyclacel Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	28 September 2015
Primary completion	4 October 2022
Estimated completion	25 August 2023
Sites	1 location across United States

Drugs / interventions tested

CYC065 — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

Cyclacel Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, single arm, dose escalation study in patients with advanced cancers.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cyclin D1, cancer progression, and opportunities in cancer treatment.
Qie S, Diehl JA. · · 2016 · cited 527× · PMID 27695879 · DOI 10.1007/s00109-016-1475-3
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
Frame S, Saladino C, MacKay C, Atrash B, et al · · 2020 · cited 68× · PMID 32645016 · DOI 10.1371/journal.pone.0234103
The Renaissance of Cyclin Dependent Kinase Inhibitors.
Ettl T, Schulz D, Bauer RJ. · · 2022 · cited 50× · PMID 35053461 · DOI 10.3390/cancers14020293
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
Jhaveri K, Burris Rd HA, Yap TA, Hamilton E, et al · · 2021 · cited 40× · PMID 34176404 · DOI 10.1080/14737140.2021.1944109
Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.
Zabihi M, Lotfi R, Yousefi AM, Bashash D. · · 2023 · cited 37× · PMID 35781526 · DOI 10.1007/s00432-022-04135-6
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Giannone G, Tuninetti V, Ghisoni E, Genta S, et al · · 2019 · cited 29× · PMID 31083638 · DOI 10.3390/ijms20092353
The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer.
Alexandrou S, George SM, Ormandy CJ, Lim E, et al · · 2019 · cited 24× · PMID 30720718 · DOI 10.3390/ijms20030667
CDK9 inhibitors in multiple myeloma: a review of progress and perspectives.
Borowczak J, Szczerbowski K, Ahmadi N, Szylberg Ł. · · 2022 · cited 23× · PMID 35092513 · DOI 10.1007/s12032-021-01636-1

Verify or expand the search:

Other trials of CYC065

Trials testing the same drug.

NCT04017546 — CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS · Phase 1 · completed
NCT03739554 — CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL · Phase 1 · completed

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Cyclacel Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT05817890 — Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects · EARLY_PHASE1 · completed
NCT04983810 — A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma · Phase 1, PHASE2 · unknown
NCT04017546 — CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS · Phase 1 · completed
NCT03884829 — A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS · Phase 1 · terminated
NCT03739554 — CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02552953 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cyclacel Pharmaceuticals, Inc.
Last refreshed: 31 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02552953.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing